Home › Cases › Hypertensive Emergency — Intracranial Haemorrhage
Hypertensive Emergency
Hypertensive Emergency — Intracranial Haemorrhage
6 questions
Question 1 · ICH + hypertension
Correct answer: Target SBP 140-160 mmHg (ESO/NICE guideline). Avoid excessive reduction
Why
ICH blood pressure management: INTERACT2/ATACH-2 trials. Target SBP 140–160 mmHg. SBP >180 → haematoma expansion risk. But overly aggressive lowering (to SBP 110–120) → worse neurological outcomes (ATACH-2 stopped early). IV labetalol or nicardipine for rapid BP control.
Key point
ICH: target SBP 140–160 mmHg. Avoid both extremes. IV labetalol or nicardipine for acute control.
Question 2 · Anticoagulation reversal
Correct answer: Immediate reversal: IV vitamin K 5-10mg AND prothrombin complex concentrate (PCC) 4-factor. Target INR <1.5 within 1 hour
Why
Warfarin-associated ICH: immediate reversal is critical (haematoma expands with ongoing anticoagulation). PCC (4-factor: Beriplex/Octaplex) reverses warfarin immediately (vs FFP which is slower and volume-limited). IV vitamin K 5–10mg (sustains reversal). Target INR <1.5 within 1h. FFP is inferior to PCC for speed.
Key point
Warfarin ICH: PCC 4-factor NOW + IV vitamin K 5–10mg. Target INR <1.5 within 1h. PCC is faster than FFP.
Question 3 · DOAC reversal in ICH
Correct answer: Andexanet alfa (for Xa inhibitors — apixaban, rivaroxaban) or idarucizumab (for dabigatran). Activated charcoal if <2h from last dose
Why
DOAC reversal in ICH: apixaban/rivaroxaban (Factor Xa inhibitors) → andexanet alfa (AndexXa) — licensed reversal agent. Dabigatran (direct thrombin inhibitor) → idarucizumab (Praxbind). PCC (non-specific) used if specific agents unavailable. Activated charcoal within 2h of last dose if safe (reduces absorption).
Key point
DOAC ICH reversal: andexanet alfa for Xa inhibitors (apixaban/rivaroxaban), idarucizumab for dabigatran.
Question 4 · Neurosurgical referral
Correct answer: NICE/STICH criteria: surgery may benefit lobar haematomas >3cm near cortex, haemorrhage causing hydrocephalus (EVD), or deteriorating patient. Deep basal ganglia haematomas: surgery usually not beneficial
Why
ICH surgery (STICH trials): deep haematomas (basal ganglia, thalamus): surgery generally no benefit. Lobar haematomas >3cm near cortex in deteriorating patient: may benefit. Cerebellar haematoma >3cm: urgent surgical evacuation. Hydrocephalus from IVH: external ventricular drain. All cases: urgent neurosurgery discussion.
Key point
ICH surgery: deep haematomas usually no surgery. Cerebellar >3cm = urgent. Hydrocephalus = EVD. Discuss neurosurgery.
Question 5 · Restarting anticoagulation
Correct answer: Specialist-led decision: typically restart DOAC 4-8 weeks after ICH if AF-associated stroke risk high. Balance bleeding vs thromboembolism risk with neurology/haematology
Why
Anticoagulation restart after ICH: complex decision — AF causes 25–30% of ischaemic strokes, yet ICH recurrence risk is 3% per year on anticoagulation. Current guidance: restart DOAC 4–8 weeks post-ICH in selected patients (lobar haematoma highest recurrence risk). AREST/APACHE trials ongoing. MDT decision.
Key point
Restarting anticoagulation after ICH: MDT decision at 4–8 weeks. Balance AF stroke risk vs ICH recurrence. Lobar = highest risk.
Question 6 · Hypertensive encephalopathy
Correct answer: Hypertensive encephalopathy — cerebral autoregulation failure, cerebral oedema without infarction. PRES (Posterior Reversible Encephalopathy Syndrome) on MRI
Why
Hypertensive encephalopathy: extreme BP causing autoregulation failure → vasogenic oedema. MRI: PRES (posterior reversible encephalopathy syndrome) — occipital white matter oedema. Treat with IV labetalol or nicardipine. Target: reduce MAP by 20–25% in first hour. NOT to normal — risks ischaemia.
Key point
Hypertensive encephalopathy: PRES on MRI. Reduce MAP by 20–25% in 1h only. Not to normal — risks ischaemia.
Case complete
Practice on this page does not update your app progress. Open the browser app if you want its learning tools and progress record.